The arterial network was informed for the first time that Ariemedi (Chinese name: Ai Ruimai Medical Technology), a medical technology company focused on medical mixed reality, has recently received tens of millions of Pre-A rounds of financing. The investor in this round is Puhua Capital.
Ariemedi mainly integrates 3D image data (MRI or CT) obtained before surgery with real-time acquired 2D image data (ultrasound, X-ray or endoscope) for real-time fusion navigation, and will be planned through intraoperative real-time spatial registration technology. The surgical path and the three-dimensional structure of the organ are provided to the doctor, and at the same time, the three-dimensional motion information of the organ is estimated and predicted in real time by the motion analysis technique. Relying on Mixed Reality Technology (MR), 3D and 2D information is displayed in real time in the doctor's field of vision.
Ariemedi uses mixed reality technology to increase the amount of field information that doctors can perceive more than 10 times, making the tissue and organ structure of the surgical area completely visible to doctors and avoiding surgical errors.
Ariemedi is dedicated to the development and production of systems and equipment for endoscopic, ultrasound and X-ray guided surgical navigation. The new navigation products developed for use in a variety of minimally invasive procedures include: tumors (cranial tumors, liver and kidney tumors, lung cancer, etc.) ), accurate diagnosis and treatment of vascular diseases (coronary heart disease, aortic dissection, hemangioma, etc.), skeletal diseases (hip and knee prosthesis replacement, spinal repair, etc.).
The systems and equipment developed by Ariemedi will make minimally invasive surgery more efficient, safer and smarter. The company uses MR, AI, human-computer interaction and image processing technology to realize the real-time fusion display of multi-modal medical images in the operation, which significantly enhances the doctor's perception and recognition of the organ tissues in the patient, so that the organization and organ structure of the operation area is completely complete for the doctor. It can be seen that solving the "blind zone" problem in doctors' surgery makes high-risk and complicated minimally invasive surgery more controllable and achieves accurate diagnosis and treatment.
At present, in minimally invasive surgery, due to the small field of surgery, doctors need to model their brains according to their own experience. The surgery relies heavily on doctors' experience. The auxiliary navigation system for minimally invasive surgery is of great significance and huge market in the clinic. Medtronic, Brainlab, Xion, Scopis and other international medical equipment manufacturers have invested a lot of research and development resources in minimally invasive surgery navigation.
The surgical navigation market is mainly monopolized by Europe and the United States. According to data from 2016, among the surgical navigation products approved, BrainLAB accounted for 32.5% of the surgical navigation products company, Brainlab AG accounted for 20%, and Medtronic accounted for 15%. Stryker accounts for 10% of the company and other companies. Increasing investment in research and development on surgical navigation is a short-term solution for the technological innovation of medical devices in China. The National "13th Five-Year Plan for Medical Device Technology Innovation" clearly pointed out that it is necessary to accelerate the development of cutting-edge technologies such as virtual reality, augmented reality, and positioning navigation.
Ariemedi has achieved rapid growth since its inception in 2016. In two years, Ariemedi experienced two rounds of financing and was selected into the Guancun high-tech enterprise. Now it has settled in Shijiazhuang and started the construction of a 2000 square meter production base.
Now that the “blind zone†of minimally invasive surgery is large, Ariemedi allows doctors to “see through†surgery to reduce the risk of surgery.
Minimally invasive surgery has a small wound, less intraoperative blood loss, and quick recovery after surgery. It has been widely used in clinical diagnosis and treatment. Currently, intraoperative real-time guided images mainly include endoscopes, ultrasound, and X-rays.
The endoscopic guided surgery delivers the endoscope to the lesion in the body, and performs the operation under the direct endoscope. Endoscopic guided surgery has changed the diagnosis and treatment of traditional surgery, reducing the damage to the skin, soft tissue and bone structure, and reducing the probability of surgical complications.
However, the endoscope can only display the surface information in the cavity, can not see the subcutaneous tissue structure, in addition, the endoscope operation space is small, the operation depends heavily on the doctor's experience, the process is complicated for the inexperienced doctor or anatomical structure The lesion area is highly dangerous. In response to this problem, Ariemedi built the endoscope parameter model in real time through virtual path planning, endoscopic calibration and dynamic calibration technology, and then realized the accurate real-time navigation of the intraoperative endoscope through virtual and real fusion rendering technology, guiding the accurate positioning of the surgical instrument. The lesion is treated with high efficiency.
Endoscopic guided surgery history
Ultrasound is one of the main guiding images of interventional therapy for liver and kidney tumors. China is a country with high incidence of liver cancer. The number of new liver cancer patients is about 395,000, and the death rate is 383,000. It is growing at a rate of 5%. Half of the world's liver cancer patients are from China.
In the treatment of liver diseases, the liver is affected by the breathing, resulting in a large non-rigid movement, which seriously affects the estimation of the position of the lesion by the surgeon during surgery, thereby greatly reducing the accuracy of the operation. Ariemedi constructed a respiratory motion model and an incompressible deformation model of the liver using four-dimensional CT images. The respiratory motion model corrects the respiratory motion during the puncture process, which not only provides the doctor with accurate lesion location, but also reflects the accuracy between the surgical instrument and the lesion. The spatial relative relationship makes the microwave ablation process of liver cancer more precise. In addition, the constructed incompressible deformation model can be used for accurate quantitative evaluation after liver cancer microwave ablation.
Liver cancer minimally invasive treatment equipment sales ratio and registration time
X-ray guidance is the main approach for the diagnosis and treatment of vascular diseases. Taking the type B aortic dissection as an example, the rate of misdiagnosis and missed diagnosis is as high as 70%. If it is not treated in time, the probability of forming a dissection aneurysm within 5 years is more than 50%, and once the rupture rate reaches 85%. Currently, X-ray guided endovascular repair (TEVAR) is the main treatment for type B aortic dissection.
X-ray is a perspective projection imaging. In the process of imaging, a large amount of spatial stereo information is lost. Doctors can only judge the lesion according to a few two-dimensional projection images. The subjectivity is strong, and the surgical effect depends heavily on the doctor's experience. Ariemedi's three-dimensional reconstruction of blood vessels can effectively compensate for the lack of X-ray imaging. It can provide doctors with intuitive, three-dimensional information on the four-dimensional structure of blood vessels, which can help doctors accurately measure the diameter, length, cross-sectional area and optimal viewing angle of blood vessels. . In addition, Ariemedi's vascular 2D-3D real-time fusion system helps doctors accurately sense vessel depth and topology for accurate diagnosis and interventional treatment of cardiovascular disease.
Domestic and international B-type sandwich TEVAR treatment ratio
Cong Weijian told reporters that although minimally invasive surgery has many advantages, minimally invasive surgery has encountered many limitations in clinical practice. Minimally invasive surgery is difficult, and it is very difficult to handle complex tissue structures. In addition, minimally invasive surgical instruments require high technical skills for doctors, and it is not easy for ordinary doctors to get started. These factors have led to the inefficiency of minimally invasive surgery in some clinical applications, relying heavily on physician experience and limiting the promotion of minimally invasive surgery.
In the mixed reality surgical navigation technology, Ariemedi has the unique advantage of real-time fusion of multiple modal medical images, improving doctors' perception of the three-dimensional and four-dimensional structure of human tissue in the surgical area, real-time movement of organs and tissues and deformation. It is estimated that reducing the difficulty of operation of minimally invasive surgery, improving the efficiency of surgery and reducing the risk of surgery.
The team is deeply cultivating scientific research, combining production, study and research.
Ariemedi is a high-tech enterprise transformed from Beijing Institute of Technology. It has established close cooperation with the top three hospitals such as the People's Liberation Army General Hospital, Union Hospital, West China Hospital, China-Japan Hospital, Anzhen Hospital and Shanghai Jiuyuan Hospital. Intensive cooperation with many domestic listed companies such as Shanghai Weichuang, and won the title of “Zhongguancun High-tech Enterprise†in early 2018.
The company relies on the research team of Beijing Institute of Technology for a long time to do research work on mixed reality, medical image intelligence analysis, surgical navigation and human-computer interaction. He has won more than 20 national 973, National 863, 12th Five-Year Support Project, 13th Five-Year Key R&D Program, National Natural Science Foundation Key Project, and National Natural Science Foundation Major Instrument Special. The R&D team is an excellent research team of the 10th Five-Year Plan, the Eleventh Five-Year Plan and the Twelfth Five-Year Plan.
The R&D team and the ENT General Hospital of the People's Liberation Army jointly undertook the 863 goal-oriented project and developed the first augmented reality surgical navigation system for the diagnosis and treatment of skull base tumors. He cooperated with the Department of Interventional Ultrasound of the General Hospital of the Chinese People's Liberation Army to undertake the 12th Five-Year Support Program, developed a hybrid reality-based endoscopic guided surgical navigation system and an ultrasound-guided surgical navigation system, and carried out a large number of clinical research work. At present, with the People's Liberation Army General Hospital, Peking Union Medical College Hospital, Beijing Anzhen Hospital, Shanghai Jiuyuan, Shanghai Weichuang Company and other institutions to undertake a number of national 13th five-year "digital diagnosis and treatment equipment research and development" key special research work, is developing A mixed reality precision surgical navigation system for liver cancer, lung cancer, hip and knee replacement, and aortic dissection.
Beijing Institute of Technology is directly under the Ministry of Industry and Information Technology of the People's Republic of China and has strong scientific research strength. In the field of arterial network (micro-signal: vcbeat), the number of experts in the research and field of 73 experts (including the Institute of Computer Science, Institute of Acoustics, Software Institute, and Automation Institute of the Chinese Academy of Sciences) last year was ranked before the Beijing Institute of Technology. 10 seats.
Ariemedi's core R&D team is from the Institute of Optoelectronics of Beijing Institute of Technology, and is based on the national “Beijing Mixed Reality and New Display Engineering Technology Research Center†and “Key Laboratory of Photoelectric Imaging Technology and Systems Ministry of Educationâ€. The core R&D personnel have research experience in virtual reality and augmented reality, artificial intelligence, human-computer interaction, medical image analysis and computer vision, and have gathered top talents in the field of mixed reality at home and abroad.
Ariemedi's R&D team has more than ten years of research and industry cooperation experience in these fields, has a strong research base and experience, has published a large number of top papers, and has won several national and provincial awards. The research results of the company's R&D team have published more than 80 papers on high-level SCI journals, and have applied for more than 60 national invention patents, and more than 20 have been authorized. The research results won the first prize of the Ministry of Education Technology Invention in 2014 and the second prize of the National Technology Invention in 2017.
Accelerate market layout and expand overseas business
At present, Ariemedi's domestic market road has begun. Ariemedi aims at domestic and foreign markets and has cooperated with dozens of top medical institutions and hospitals in the country and clinical system testing. In the industry, Ariemedi actively cooperates with medical device companies such as Shanghai Weichuang to promote the application of mixed reality technology in clinical diagnosis and treatment.
This round of financing will also accelerate the market layout and product landing. Ariemedi founder Cong Weijian told the arterial network reporter that this round of funds mainly has three purposes:
First, the funds will be used for production base construction, CFDA clinical certification and medical device registration certificate approval.
Second, expand the mixed-reality medical development team, increase the scope of clinical product cooperation, and accelerate the transformation of diversified products.
Third, complete the layout of the mixed reality medical industry chain. Based on the in-depth cooperation of more than ten top medical institutions in China, Ariemedi will cooperate with more medical institutions and manufacturers around the world to gradually expand its business in Europe and the United States.
Organic turmeric extract is derived from the dried rhizomes of turmeric. Turmeric is a ginger plant with a botanical name of Curcuma longa L. The main ingredients of turmeric extract are curcumin. And the curcumin ratio can reach 95% or more. Turmeric has long been used as a natural pigment (E100) in the food industry. It has strong tinting strength, does not fade, but is sensitive to light, heat. Mainly used for dyeing canned foods, sausage products, and sauces.
Turmeric Extract,Organic Turmeric Extract,Turmeric Extract Powder,Organic Turmeric Root
Organicway (xi'an) Food Ingredients Inc. , https://www.organicwayince.com